早期匹伐他汀治疗对急性冠脉综合征患者冠状动脉纤维帽厚度的影响:光学相干断层扫描评估的ESCORT研究
ESCORT研究为前瞻性随机活性对照单中心研究,纳入53例急性冠脉综合征合并未治疗血脂异常患者,1:1随机分为早期他汀组(基线起匹伐他汀4 mg/日)与晚期他汀组(基线后3周起同剂量)。光学相干断层扫描评估非罪犯冠状动脉斑块,结果显示基线至3周随访早期组纤维帽厚度增加(140 μm至160 μm,p=0.017),晚期组降低(135 μm至130 μm,p=0.020),早期组增加百分比显著大于晚期组(8.3% vs -5.8%,p<0.001);基线至36周两组纤维帽厚度增加程度相当。
要点
- 早期匹伐他汀治疗3周内可增加急性冠脉综合征患者非罪犯斑块的纤维帽厚度,晚期他汀组同期降低。
- 基线至3周纤维帽厚度增加百分比早期组8.3% vs 晚期组-5.8%(p<0.001),早期组显著更大。
- 基线至36周随访,两组纤维帽厚度增加程度相当。
核心结论
- 急性冠脉综合征患者早期给予匹伐他汀4 mg/日可在随访前3周内增加冠状动脉斑块纤维帽厚度,并在36周随访期间进一步增加。
研究设计与样本
- 前瞻性、随机、活性对照、单中心研究,纳入53例急性冠脉综合征合并未治疗血脂异常患者,1:1随机分为早期他汀组(基线起匹伐他汀4 mg/日)与晚期他汀组(基线后3周起匹伐他汀4 mg/日),在基线、3周和36周随访时用光学相干断层扫描评估非罪犯冠状动脉斑块。
关键影像表现/征象
- 早期他汀组基线至3周随访纤维帽厚度从140 μm(IQR 120至170 μm)增加至160 μm(IQR 130至190 μm),p=0.017。
- 晚期他汀组基线至3周随访纤维帽厚度从135 μm(IQR 110至183 μm)降低至130 μm(IQR 108至160 μm),p=0.020。
- 基线至3周随访纤维帽厚度增加百分比早期他汀组8.3%(IQR 0.0%至21.4%)vs 晚期他汀组-5.8%(IQR -16.0%至0.0%),p<0.001。
- 基线至36周随访,两组纤维帽厚度增加程度相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of the present study was to assess the effect of early statin therapy on fibrous-cap thickness in coronary plaques of patients with acute coronary syndrome (ACS) by using optical coherence tomography.
BACKGROUND: Statins can contribute to the stabilization of coronary plaques.
METHODS: This is a prospective, randomized, active-controlled, single-center study. Patients with ACS and untreated dyslipidemia were enrolled and randomly allocated (ratio 1:1) to either the early statin group (received pitavastatin 4 mg/day from baseline) or the late statin group (received pitavastatin 4 mg/day from 3 weeks after the baseline). Optical coherence tomography was performed at baseline, 3-week, and 36-week follow-up to assess nonculprit coronary plaques in 53 patients.
RESULTS: Between baseline and 3-week follow-up, fibrous-cap thickness increased in the early statin group (140 μm [interquartile range (IQR):120 to 170 μm] to 160 μm [IQR: 130 to 190 μm]; p = 0.017), but decreased in the late statin group (135 μm [IQR: 110 to 183 μm] to 130 μm [IQR: 108 to 160 μm]; p = 0.020). The percentage of increase in fibrous-cap thickness between baseline and 3-week follow-up was significantly greater in the early statin group compared with the late statin group (8.3% [IQR: 0.0% to 21.4%] vs. -5.8% [IQR: -16.0% to 0.0%]; p < 0.001). Between baseline and 36-week follow-up, fibrous-cap thickness increased comparably in the 2 groups.
CONCLUSIONS: Early therapy with pitavastatin 4 mg/day for patients with ACS provided an increase in fibrous-cap thickness in coronary plaques during the first 3 weeks of follow-up and a further increase during 36 weeks of follow-up. The study was registered with UMIN Clinical Trial Registry (Effect of PitavaStatin on Coronary Fibrous-cap Thickness-Assessment by Fourier-Domain Optical CoheRence Tomography [ESCORT]; UMIN000002678).
引用
- Nishiguchi T, Kubo T, Tanimoto T, et al. Effect of Early Pitavastatin Therapy on Coronary Fibrous-Cap Thickness Assessed by Optical Coherence Tomography in Patients With Acute Coronary Syndrome: The ESCORT Study. JACC Cardiovasc Imaging. 2017. PMID: 28917689. doi:10.1016/j.jcmg.2017.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。